论文部分内容阅读
目的探讨食管癌放疗前后血清转化生长因子β１（ＴＧＦβ１）水平改变与放疗疗效及预后的关系。方法：采用ＥＬＩＳＡ方法检测５６例明确诊断的食管癌患者放疗前后的血清ＴＧＦβ１水平，并将其与病变范围、部位、Ｘ线病理分型、近期疗效及转移复发的关系进行对比分析。结果：放疗前食管癌患者血清ＴＧＦβ１平均水平明显高于正常对照组（Ｐ＜０．０１），血清ＴＧＦβ１的表达与病变部位、病变长度、Ｘ线病理分型无关（Ｐ＞０．０５）；放疗后血清ＴＧＦβ１水平下降（Ｐ＜０．０５），其改变与近期疗效及转移复发相关（Ｐ＜０．０１）。结论：血清ＴＧＦβ１水平可作为监测食管癌近期放疗疗效和预后、提示后续或辅助治疗的一项参考指标。
Objective To investigate the relationship between the changes of serum transforming growth factor-β1 (TGFβ1) levels and radiotherapy outcomes and prognosis before and after radiotherapy for esophageal cancer. Methods: Serum TGFβ1 levels in 56 patients with esophageal cancer who had been diagnosed with radiotherapy before and after radiotherapy were detected by ELISA. The levels of serum TGFβ1 in patients with esophageal cancer before and after radiotherapy were compared with pathological changes, location, X-ray pathology, short-term efficacy, metastasis and recurrence. Results: The serum TGFβ1 level in esophageal cancer patients before radiotherapy was significantly higher than that in the normal control group (P<0.01). The expression of serum TGFβ1 was not associated with lesion location, lesion length, and X-ray pathological type (P>0.05). The serum TGFβ1 levels decreased after radiotherapy (P<0.05), and the changes were related to the short-term efficacy, metastasis and recurrence (P<0.01). Conclusion: Serum TGFβ1 level can be used as a reference index to monitor the efficacy and prognosis of recent radiotherapy for esophageal cancer, prompt follow-up or adjuvant therapy.